The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

BRAF Inhibitor

Geo Regions

BRAF Inhibitor
Share to an HCP

Overview + Rationale

Overview

  • B-Raf is a member of the Raf kinase family of growth signal transductionprotein kinases. This protein plays a role in regulating the MAP kinase/ERKssignaling pathway, which affects cell division, differentiation, and secretion
  • Activating mutations in BRAF lead to constitutive activation of BRAF and henceRAF-MEK-ERK signaling cascade, promoting cell proliferation and survival whileinhibiting apoptosis, and thus driving cancer growth
  • Mutations in this gene, most commonly the V600E mutation, are the mostfrequently identified driver mutations in melanoma
  • BRAF mutations have also been identified in various other cancers includingcolorectal cancer, thyroid carcinoma, non-small cell lung cancer, and hairy cellleukemia

Stage of Development

dummy
BRAF V600E-mutant+Metastatic ColorectalCancer (mCRC)
Phase 3 Combination(First Line)